Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8N4J0
UPID:
CARME_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N4J0; Q7Z383; Q8N7C5
Background:
Carnosine N-methyltransferase is a pivotal enzyme that catalyzes the formation of anserine from carnosine, playing a crucial role in vertebrate skeletal muscles. It specifically targets L-histidine-containing di- and tripeptides, including Gly-Gly-His and homocarnosine, for methylation.
Therapeutic significance:
Understanding the role of Carnosine N-methyltransferase could open doors to potential therapeutic strategies. Its involvement in muscle physiology suggests its potential in treating muscle-related disorders.